Publication:
P-cadherin, Vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study

Thumbnail Image
Files
Pcadherin Vimentin and CK14 for identification of basallike phenotype in breast carcinomas an immunohistochemical study.pdf(413.9 KB)
Date
2010
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Sousa, Bárbara ; Paredes, Joana ; Milanezi, Fernanda ; Lopes, Nair ; Martins, Diana ; Dufloth, Rozany ; Vieira, Daniella ; Albergaria, André ; Veronese, Luiz ; Carneiro, Vitor ; Carvalho, Silvia ; Costa, José Luis ; Zeferino, Luiz ; Schmitt, Fernando
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Introduction: The most suitable immunohistochemical criterion to identify basal-like breast carcinomas (BLBC), a molecular subgroup of breast cancer associated with poor prognosis, is the triple negative phenotype along with CK5 and/or EGFR immunoreactivity. However, several putative basal markers have been suggested as alternatives to identify BLBC with more accuracy. Experimental Design: The expression of CK5, EGFR, P-cadherin, CK14, Vimentin and p63 were evaluated in 462 invasive breast carcinomas to determine their sensitivity and specificity for BLBC identification. Results: P-cadherin and CK5 showed higher sensitivity values, while EGFR, Vimentin and CK14 were the most specific markers. The combination of CK5 with P-cadherin, Vimentin or CK14 proved to be a reliable option for distinguishing the basal phenotype, compared to the “gold standard” pair CK5/EGFR. Furthermore, P-cadherin was still able to recognize a large number of putative BLBC among the “unclassified” group (ER-/PR-/HER2-/CK5-/EGFR-). Conclusions: P-cadherin, Vimentin and CK14 can recognize BLBC already identified in triple negative/ CK5 and/or EGFR+ tumors, and due to P-cadherin sensitivity for BLBC identification this marker can reliably recruit a large number of breast carcinomas with basal phenotype among immunohistochemistry triple negative/ CK5 and/or EGFR - pool of tumors. Although they need GEP validation, our results can introduce the idea of these markers as additional options in the daily workup of breast pathology laboratories to identify BLBC.
publication.page.subject
Breast cancer , Immunohistochemical
Citation
URI
http://hdl.handle.net/10201/46327
item.page.embargo
Collections
Histology and histopathology Vol.25, nº8 (2010)
Ir a Estadísticas